Ideas

February 2, 2018

Published by admin_auro at February 2, 2018

Categories

Molecular therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Rosuvastatin, Docosahexaenoic acid and 5 aminolevulinic acid decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 3/February/2018, 12.29 am

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and […]

February 2, 2018

Published by admin_auro at February 2, 2018

Categories

Cardiac rejuvenation therapy: A therapeutic mix encompassing Aspirin and Hydralazine suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 3/February/2018, 12.20 pm

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Cardiac rejuvenation therapy: A therapeutic mix encompassing Aspirin and Hydralazine suppresses tumor suppressor INK4a/p16 expression, […]

February 2, 2018

Published by admin_auro at February 2, 2018

Categories

Molecular therapy for inflammation and arthritis: A pharmaceutical mixture encompassing Naproxen and Aspirin increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 3/February/2018, 12.09 am

Introduction: What they say A study from Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany shows that […]

February 2, 2018

Published by admin_auro at February 2, 2018

Categories

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Sitagliptin (PAS) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 2/February/2018, 11.58 pm

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]